Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
13vTwZPeAszk2C40
